The 10 Highest-Revenue Biologics and Their Purple Book Exclusivity Timelines

For market access leaders, commercial strategists, and life sciences analysts, revenue concentration among blockbuster therapies makes exclusivity forecasting essential. The largest biological franchises generate tens of billions in annual sales, and their loss-of-exclusivity (LOE) events represent massive patent cliffs and major biosimilar entry opportunities.

This guide provides an auditable analysis of the 10 highest-revenue biological products within a strictly defined regulatory scope: licensed biological products approved under section 351(a) of the Public Health Service (PHS) Act. It explicitly excludes conventional small-molecule medicines and synthetic peptides approved through new drug applications (NDAs)—such as Ozempic (semaglutide, NDA 209637) or Biktarvy (bictegravir combo, NDA 210251)—which operate under the Hatch-Waxman FD&C Act rather than the Purple Book biologics framework.

Below, we detail our multi-source intelligence methodology, present the comprehensive exclusivity timeline table, and examine how Reference Product Exclusivity (RPE) and Orphan Drug Exclusivity (ODE) govern the competitive horizon.

Table of contents

• Defining the 351(a) Biological Comparison Universe
• Methodology: The 4-Stage Exclusivity Intelligence Pipeline
• The 10 Highest-Revenue Biologics: Complete Exclusivity Timeline
• How Reference Product Exclusivity Operates under the PHS Act
• Orphan Drug Exclusivity: Indication-Level Protection
• Why the Purple Book Alone Is Insufficient for Indication-Level ODE
• Key Exclusivity Profiles of the Top Blockbusters
• Analytical Traps to Avoid
• Track Biologic Exclusivity in QOPE
• Sources

Defining the 351(a) Biological Comparison Universe

The FDA Purple Book is the official federal catalog for licensed biological products. Its database encompasses products regulated by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), including innovator reference products, biosimilars, interchangeable biosimilars, vaccines, and cellular therapies.

To ensure regulatory integrity, our analysis is strictly restricted to licensed biological products under section 351(a) of the PHS Act.

This distinction is fundamental:

1. Biologics (PHS Act § 351): High-molecular-weight molecules (monoclonal antibodies, fusion proteins, enzymes) licensed under BLAs. Follow the BPCI Act biosimilar pathway (section 351(k)) and receive 12 years of reference product exclusivity.
2. Small Molecules & Peptides (FD&C Act § 505): Chemical drugs approved under NDAs. Follow Hatch-Waxman generic pathways (section 505(j)) and receive 5-year new chemical entity (NCE) or 3-year new clinical investigation exclusivity.

Treating products across these distinct regimes as interchangeable corrupts forecasting models. Our top-10 set includes only genuine 351(a) reference biologics.

Methodology: The 4-Stage Exclusivity Intelligence Pipeline

Revenue rankings and regulatory timelines must be reproducible from primary sources. Because the Purple Book does not track commercial revenues or provide granular indication-by-indication historical orphan histories, we establish a 4-stage intelligence pipeline:

1. Audited Financial Baseline (SEC EDGAR): We establish a single, standardized reporting baseline using FY2023 audited global net product sales extracted directly from corporate annual reports and SEC filings (Form 10-K for US filers, Form 20-F / IFRS annual statements for foreign issuers). This avoids the distortions of mixed reporting quarters or unverified market estimates.
2. BLA Normalization: We isolate the primary Section 351(a) Biologics License Application (BLA) associated with each global product franchise, strictly excluding small molecules, vaccines, and non-biologic drug combinations.
3. Purple Book RPE & Licensure Baseline: We query the FDA Purple Book database for each BLA to verify the official date of first licensure, the 12-year Reference Product Exclusivity (RPE) expiration date, and the primary BLA regulatory status.
4. FDA Orphan Drug (OOPD) Database Integration: Because the Purple Book displays only the latest orphan expiration date when multiple orphan periods exist, we cross-reference each product against the FDA Orphan Designated and/or Approved Products database to map individual orphan designations, approved indications, and indication-specific 7-year ODE expirations.

The 10 Highest-Revenue Biologics: Complete Exclusivity Timeline

The table below summarizes the 10 highest-revenue PHS Act biologics, integrating audited FY2023 financial filings with official Purple Book and FDA Orphan Drug database milestones:

Data Sources: FY2023 Form 10-K / Form 20-F Annual SEC Filings; FDA Purple Book Database (September 2026 snapshot); FDA Orphan Designated and/or Approved Products Database.

How Reference Product Exclusivity Operates under the PHS Act

Section 351(k)(7) of the PHS Act defines the statutory protection period for reference biologics:

• 12 Years of Market Exclusivity: An application for a biosimilar product under section 351(k) cannot be approved by the FDA until 12 years after the date of first licensure of the reference product.
• 4-Year Filing Barrier: A biosimilar applicant may not even submit a 351(k) application to the FDA until 4 years after the reference product’s first licensure date.

This 12-year statutory term is unique to biologics. It is vastly longer than the standard 5-year New Chemical Entity (NCE) exclusivity granted to small-molecule drugs under the Hatch-Waxman framework.

However, analysts must recognize that reference product exclusivity is a regulatory floor, not an automatic commercial launch date. Patent estates—such as formulation patents, manufacturing methods, and administration regimens—frequently protect products for years after their 12-year RPE has expired.

Orphan Drug Exclusivity: Indication-Level Protection

While Reference Product Exclusivity protects the biological entity at the molecular level, Orphan Drug Exclusivity (ODE) provides 7 years of market protection for designated rare disease indications.

Under section 527 of the FD&C Act (which applies to both drugs and biologics):

1. Indication-Specific Scope: ODE prevents the FDA from approving another version of the same product for the same rare disease indication for 7 years.
2. Label Carve-Outs (Skinny Labels): A biosimilar manufacturer can potentially seek approval for all non-orphan indications once 12-year RPE expires, while "carving out" protected orphan indications from its label until the 7-year ODE term elapses.
3. Cumulative Protection: Blockbuster biologics like Keytruda (pembrolizumab) frequently receive orphan designations for niche pediatric or rare oncology sub-types late in their lifecycles. For example, Keytruda BLA 125514 reached its 12-year reference product exclusivity expiration in September 2026, but it retains active orphan exclusivity on specific indications into 2028–2031.

Why the Purple Book Alone Is Insufficient for Indication-Level ODE

A critical methodological insight for life sciences analysts is understanding the architectural limitations of the Purple Book regarding orphan exclusivity.

As the FDA clarifies in its Purple Book FAQ, when a biological product has been granted multiple periods of orphan exclusivity across different rare indications, the Purple Book's Orphan Exclusivity Expiry Date column displays only the single latest expiration date.

Consequently, relying exclusively on the Purple Book creates significant analytical blind spots:

• Concealed Milestone Expirations: Earlier orphan indications that have already expired (such as Keytruda's orphan exclusivity for Merkel cell carcinoma or MSI-H cancer) are overwritten in the Purple Book summary field by later approvals.
• Inability to Model Skinny-Label Launches: To model which indications a biosimilar applicant can legally launch upon 12-year RPE expiry versus which indications must be carved out, analysts cannot rely on a single date.
• The Required Cross-Walk: Analysts must cross-walk the Purple Book BLA number to the FDA Orphan Designated and/or Approved Products (OOPD) database. The OOPD database records each separate orphan designation, designated indication, FDA approval date, and exact 7-year exclusivity period.

Key Exclusivity Profiles of the Top Blockbusters

1. Keytruda (pembrolizumab) — The Oncology Mega-Franchise

• Primary BLA: 125514 (Merck & Co., Inc.)
• Audited Revenue: $25.01B (FY2023 Form 10-K)
• First Licensure: September 4, 2014
• Exclusivity Profile: Reached its 12-year RPE milestone on September 4, 2026. While core molecular exclusivity has expired, biosimilar entry is shaped by indication-specific orphan protections in biliary tract carcinoma (exclusivity through February 2031) and endometrial carcinoma (exclusivity through June 2031), combined with a dense patent portfolio covering subcutaneous formulations and extended dosing schedules.

2. Humira (adalimumab) — The Post-Exclusivity Benchmark

• Primary BLA: 125057 (AbbVie Inc.)
• Audited Revenue: $14.40B (FY2023 Form 10-K)
• First Licensure: December 31, 2002
• Exclusivity Profile: 12-year RPE expired in December 2014, and all orphan exclusivity protections (including hidradenitis suppurativa and uveitis) have fully elapsed. Commercial biosimilar entry was delayed until 2023 through patent thicket litigation settlements, resulting in 10 approved biosimilars (4 carrying interchangeable presentations).

3. Dupixent (dupilumab) — Long-Term Immunology Moat

• Primary BLA: 761055 (Sanofi / Regeneron Pharmaceuticals)
• Audited Revenue: $11.59B (€10.72B reported in Sanofi 20-F / Regeneron 10-K)
• First Licensure: March 28, 2017
• Exclusivity Profile: Holds 12-year RPE protection through March 28, 2029. Supplemented by active ODE protections in eosinophilic esophagitis (May 2029) and prurigo nodularis (September 2029), ensuring substantial regulatory exclusivity moats across both core and niche indications.

4. Stelara (ustekinumab) — The Current Wave of Biosimilar Launches

• Primary BLA: 125261 (Janssen / Johnson & Johnson)
• Audited Revenue: $10.86B (FY2023 Form 10-K)
• First Licensure: September 25, 2009
• Exclusivity Profile: 12-year RPE expired in September 2021. Patent litigation settlements established commercial launch windows in 2024–2025 across multiple approved biosimilars (Wezlana, Selarsdi, Otulfi), with pediatric psoriatic arthritis ODE expiring in August 2027.

5. Darzalex (daratumumab) — Subcutaneous Growth & Multiple Myeloma Moat

• Primary BLA: 761036 (Janssen / Johnson & Johnson)
• Audited Revenue: $9.74B (FY2023 Form 10-K)
• First Licensure: November 16, 2015
• Exclusivity Profile: Holds 12-year RPE through November 16, 2027. Multiple active orphan protections in combination multiple myeloma regimens extend through 2027, with light chain (AL) amyloidosis orphan exclusivity protecting the franchise through January 2028.

6. Eylea (aflibercept) — Ophthalmology Interchangeability

• Primary BLA: 125387 (Regeneron Pharmaceuticals)
• Audited Revenue: $9.38B (FY2023 Form 10-K)
• First Licensure: November 18, 2011
• Exclusivity Profile: RPE expired in November 2023. FDA approved the first biosimilar competitors in May 2024 (including interchangeable designations), while Regeneron transitions the market toward its high-dose (8 mg) formulation and defends pediatric orphan exclusivity in retinopathy of prematurity extending through February 2030.

Analytical Traps to Avoid

When building competition models from Purple Book data, analysts must avoid four common traps:

1. Confusing Regulatory Expiry with Commercial Entry: The expiration of 12-year RPE marks the legal point where FDA can approve a biosimilar. It does not prevent the reference sponsor from asserting unexpired patents in federal court.
2. Conflating Hatch-Waxman and BPCI Act Rules: Do not apply small-molecule concepts like "3-year new clinical investigation exclusivity" to biologics. Biologics are governed by 12-year RPE, 7-year ODE, and 6-month pediatric extensions under section 351(m) of the PHS Act.
3. Overlooking Indication Segmentation: Always verify whether unexpired ODE dates protect a commercially critical patient sub-population before modeling full biosimilar market penetration.
4. Treating Purple Book ODE as Complete History: Never rely solely on the Purple Book's single orphan date field; always cross-reference the FDA Orphan Drug Database to identify expired indications eligible for skinny-labeling.

Track Biologic Exclusivity in QOPE

QOPE links Purple Book regulatory determinations directly with pricing benchmarks, statutory exclusivity milestones, and claims datasets. Formulary managers and commercial analysts can review Biological Product Approval and Exclusivity Dates, consult our comprehensive FDA Purple Book Guide, or Explore Purple Book data in QOPE to model upcoming patent cliffs, loss-of-exclusivity timelines, and competitive 351(k) filings across every major therapeutic category.

By combining regulatory exclusivity dates with longitudinal utilization data, market access teams can build defensible biosimilar penetration curves, identify indication-level carve-out risks, and optimize commercial contracting well ahead of formal patent expiration dates.

Sources

• FDA Purple Book Database of Licensed Biological Products
• FDA Orphan Designated and/or Approved Products Database (OOPD)
• U.S. Securities and Exchange Commission (SEC) EDGAR Database
• FDA Purple Book Frequently Asked Questions
• FDA Frequently Asked Questions: Patents and Exclusivity
• Merck & Co., Inc. Form 10-K Annual Report (FY2023)
• AbbVie Inc. Form 10-K Annual Report (FY2023)
• Johnson & Johnson Form 10-K Annual Report (FY2023)
• Regeneron Pharmaceuticals, Inc. Form 10-K Annual Report (FY2023)
• Sanofi Form 20-F Annual Report (FY2023)
• Bristol Myers Squibb Form 10-K Annual Report (FY2023)
• Amgen Inc. Form 10-K Annual Report (FY2023)
• Roche Holding AG Annual Report (FY2023)